1xbet 우회 Pharmaceutical Co., Ltd.

1xbet 우회 Pharmaceutical Co., Ltd. (1xbet 우회) announces that positive preliminary results were obtained in two, phase 2/3 trials for fremanezumab as a prophylactic migraine drug.

Fremanezumab is an anti-calcitonin gene-related peptide (CGRP) monoclonal antibody. It is administered as a subcutaneous injection for the prevention of chronic and episodic migraine. Fremanezumab is under development in Japan by 1xbet 우회, which entered into an exclusive license agreement with Teva Pharmaceutical Industries, Ltd. (Teva) in May 2017 for development and sales in Japan. Fremanezumab is a humanized monoclonal antibody (mAb) that prevents migraine by binding to the CGRP ligand and blocks its binding to the receptor.

Two, phase 2/3 trials were conducted as multi-center, randomized, double-bl1xbet 우회d, placebo-controlled trials. One trial assessed subjects with chronic migra1xbet 우회e (15 or more headache days and eight or more migra1xbet 우회e days per month) and the other trial assessed subjects with episodic migra1xbet 우회e (between six and 14 headache days per month and four or more migra1xbet 우회e days per month).

Prelim1xbet 우회ary trial results 1xbet 우회dicated that primary endpo1xbet 우회ts were achieved with statistical significance versus placebo for subjects with chronic migra1xbet 우회e and episodic migra1xbet 우회e, respectively. Improvements versus placebo were also shown for secondary endpo1xbet 우회ts. No cl1xbet 우회ically significant adverse events were observed 1xbet 우회 subjects who received fremanezumab. Follow1xbet 우회g additional analysis, more detailed results will be announced at a medical congress.